The consequences are still flowing through the index. In its September 2026 rebalance, S&P Dow Jones Indices removed Cochlear from the S&P/ASX 50, effective 21 September, after its Market Value shrank. Cochlear (ASX:COH) remains an ASX 200 constituent and one of the healthcare sector's key names, but its role has changed. The question now is how a smaller, recovering Cochlear could influence the ASX 200: through the healthcare sector's performance, through sentiment towards premium-priced quality stocks, and through whether its FY27 guidance holds.

The Business Behind the Brand

Cochlear designs and sells implantable hearing solutions. Its core product is the cochlear implant, which bypasses damaged parts of the inner ear for people with severe to profound hearing loss. It also sells sound processor upgrades to existing recipients through its Services business, and bone-conduction devices through Acoustics.

The model has two appealing features. Each implant creates a long-term customer who may upgrade processors over many years, and the company has spent decades building relationships with surgeons, audiologists and hospitals. Its latest platform is the Nucleus Nexa System, which Cochlear says accounted for more than 95 per cent of implant sales in developed markets by June 2026.

What Went Wrong in FY26

Cochlear entered FY26 guiding for underlying net profit of A$435 million to A$460 million. With its half-year result in February, it said profit was expected to be at the lower end of that range, citing delays in the contracting process for the new implant system.

The full-year result, released on 18 August 2026, landed at the top of that revised range:

  • sales Revenue of A$2.34 billion, up 2 per cent in constant currency and down 1 per cent as reported
  • underlying net profit of A$322.4 million, down 22 per cent
  • statutory net profit of A$147.3 million, down 62 per cent, including about A$109 million of non-cash Investment write-downs, mainly linked to EpiMinder
  • gross Margin of 71 per cent, down from 74 per cent

Dividends and FY27 Guidance

Cochlear targets a payout of about 70 per cent of underlying profit, so the Dividend followed Earnings lower. The final dividend was A$1.30 a share, with an ex-date of 21 September and payment due on 14 October 2026, taking the full-year total to A$3.45 after a A$2.15 interim.

For FY27, the company guided to:

  • low single-digit sales revenue growth in constant currency
  • underlying net profit of A$330 million to A$350 million

That guidance assumes an Australian dollar of about US$0.70. Cochlear is also carrying out cost restructuring, booking about A$69 million in transitional costs in FY26, and has said it plans to invest more in reaching adults and seniors with hearing loss.

Where Cochlear Now Sits in the Index

Cochlear's influence on the ASX 200 comes through three channels.

Healthcare sector weight. Australian listed healthcare is concentrated in a small number of large companies, with Cochlear among the biggest. When Cochlear shares move sharply, as they did in April, the sector index moves with them.

Sentiment towards quality growth. Cochlear has long traded on a premium valuation because of its market leadership and steady growth. April's sell-off showed how quickly premium stocks can re-rate when guidance disappoints. A sustained recovery could support confidence in other high-multiple ASX shares; further disappointment could reinforce caution.

Index flows. Leaving the ASX 50 meant funds tracking that index had to exit their positions, while Cochlear remained in the ASX 100 and ASX 200. Its lower weighting means it now moves the broader benchmark less than it once did, but it remains a sizeable constituent.

Risks Worth Weighing

Implant growth. The key concern is whether implant revenue can grow again after a flat year, particularly with pricing, contracting and competition in developed markets.

Margins. Gross margin fell three percentage points in FY26, and recovering it depends on production volumes and costs.

Currency. Most revenue is earned offshore, so a stronger Australian dollar than the guidance assumes could reduce reported profit.

Execution. Restructuring and a shift in Marketing towards older adults could take time to show results.

Healthcare funding. Hospital budgets and reimbursement settings in key countries influence demand.

The Next Checkpoints

Annual general meeting. Cochlear's hybrid AGM is scheduled for 26 October 2026, and investors may look for commentary on first-half trading.

Half-year result. The first-half FY27 result, likely in February 2027 based on past practice, will show whether the business is tracking towards A$330 million to A$350 million.

Implant growth and Nexa uptake. Signs that unit growth is converting into revenue growth.

Currency. The Australian dollar compared with the US$0.70 guidance assumption.

Index reviews. Future S&P/ASX rebalances will reflect whether Cochlear's market value recovers.

Key Takeaways

Cochlear is no longer in the ASX 50, but that does not make it irrelevant to the broader index. It remains one of the largest healthcare stocks in the ASX 200 and a key test of how the market treats quality companies that stumble.

The FY26 result showed the business can still grow units and services even in a difficult year, while FY27 guidance implies a modest profit recovery. Whether ASX:COH delivers that recovery, and whether implant revenue returns to growth, could shape healthcare sector returns and broader sentiment towards premium Australian shares over the next 12 months.